Results 11 to 20 of about 134,214 (298)

Activation of Prothrombin

American Journal of Physiology-Legacy Content, 1958
In experiments with purified biothrombin, it was found that strong solutions of sodium citrate or protamine sulfate (0.1% w/v) or purified platelet factor 3 depress the esterase activity and leave the clotting power unaltered. Apparently a depression of esterase activity is beneficial for the autocatalytic activation of purified prothrombin.
R H, LANDABURU, W H, SEEGERS
openaire   +3 more sources

Activation of Prothrombin

American Journal of Physiology-Legacy Content, 1956
In the activation of a prothrombin solution, only part of the prothrombin becomes biothrombin, some becomes autoprothrombin I and some becomes autoprothrombin II. Thrombin-thrombin is also obtained, and perhaps other derivatives of prothrombin are formed. Prothrombin thus has multiple potentialities and these can be developed in diverse ways.
J A, PENNER, W H, SEEGERS
openaire   +3 more sources

The development of a novel native prothrombin assay for the more efficient management of oral anticoagulation therapy [PDF]

, 2004
Disturbances of the natural balance between pro-coagulant and anticoagulant systems, due to hereditary or acquired factors may result in haemorrhagic or thrombotic diseases.
Sylvester, Adrian Jose
core   +7 more sources

PURIFICATION AND CHARACTERIZATION OF A VARIANT OF HUMAN PROTHROMBIN: PROTHROMBIN SEGOVIA [PDF]

Thrombosis Research, 1997
A dysprothrombin designated prothrombin Segovia was isolated from the plasma of an individual with normal prothrombin antigen and prothrombin activity lesser than 25% of the control prothrombin activity. Activation by prothrombinase complex showed a lower amidolytic than clotting activity, which suggests a lesser generation of active intermediates than
Montaño, L.F. (Luis F.), Paramo, J.A. (José Antonio), Borbolla, J.R. (José R.), Rocha, E. (Eduardo), Collados, M.T. (María T.), Fernandez, J. (Javier), Montes, R. (Ramón)   +6 more
openaire   +5 more sources

Prothrombin Is Responsible for the Lupus Cofactor Phenomenon in a Patient with Lupus Anticoagulant/Hypoprothrombinemia Syndrome

TH Open, 2020
Lupus anticoagulant is a misnomer as it is commonly associated with thromboembolic events. In few cases, the name retains its literal meaning when it characterizes patients with a bleeding disorder.
Vittorio Pengo, Lorena Zardo, Maria Grazia Cattini, Elisa Bison, Elena Pontara, Sara Altinier, Chunyan Cheng, Gentian Denas   +7 more
doaj   +1 more source

Multivariate Analysis of Protein–Nanoparticle Binding Data Reveals a Selective Effect of Nanoparticle Material on the Formation of Soft Corona

Nanomaterials, 2023
When nanoparticles are introduced into the bloodstream, plasma proteins accumulate at their surface, forming a protein corona. This corona affects the properties of intravenously administered nanomedicines.
Susannah Emily Cornwell, Sarah Ogechukwu Okocha, Enrico Ferrari   +2 more
doaj   +1 more source

Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation [PDF]

, 2005
The Scientific Committee of Molecular Biology Techniques (C-MbT) in Clinical Chemistry of the IFCC has initiated a joint project in co-operation with the European Commission, Joint Research Centre, Institute of Reference Materials and Measurements to ...
Tosetto, Alberto, Visvikis, Sophie, RIEGER Sandra, GANCBERG D, Kitchen, Steve, MARKI-ZAY Janos, MANNHALTER C., Schimmel, Heinz G., VISVIKIS S, Gancberg, David, CORBISIER P, REITSMA Pieter, KITCHEN S, TORDAI A, Rieger, Sandra, Halbmayer, Walter-Michael, REITSMA PH, SPANNAGL M, GANCBERG David, Tordai, Attilia, Opplinger Leibundgut, Elisabeth, SPANNAGL Michael, OPPLIGER LEIBUNDGUT E, NEUMAIER Michael, Oppliger Leibundgut, Elisabeth, MELEGH B, CORBISIER Philippe, OLDENBURG Johannes, RIEGER S, Corbisier, Philippe, OLDENBURG J, COOPER S, HALBMAYER Walter-Michael, Cooper, Susan, HALBMAYER WM, COOPER Susan, KITCHEN Steve, MRKI ZAY J, Reitsma, Pieter H., Marki-Zay, János, Gemmati, Donato, TOSETTO A, VISVIKIS Sophie, TORDAI Attila, Melegh, Béla, Zadro, Renata, SCHIMMEL HG, Neumaier, Michael, KLEIN Christoph, SCHIMMEL Heinz, TOSETTO Alberto, Oldenburg, Johannes, MANNHALTER Christine, ZADRO R, Mannhalter, Christine, Klein, Christoph L., MELEGH Bela, NEUMAIER M, Spannagl, Michael, KLEIN CL, OPPLIGER LEIBUNDGUT Elisabeth, Cooper, S., GEMMATI Donato, ZADRO Renata   +63 more
core   +2 more sources

Factor V Leiden, FII G20210A, MTHFR C677T mutations as risk factors for venous thrombosis during pregnancy and puerperium [PDF]

Vojnosanitetski Pregled, 2005
Background. Venous thrombosis is the most common cause of obstetric morbidity and mortality during pregnancy and puerperium. The incidence of pregnancy associated venous thrombosis varies from 1 in 1000 to 1 in 2000 deliveries. Factor V G1691A (FV Leiden)
Đorđević Valentina, Rakićević Ljiljana B., Spasić Miloš, Miljić Predrag, Miković Danijela, Kovač Mirjana, Radojković Dragica   +6 more
doaj   +1 more source

Coagulation markers in patients with coronary artery disease

Journal of Biological Research, 2022
Coronary artery disease (CAD) is a major public health problem all over the world, and although diagnostic and treatment approaches are improving, the majority of individuals who suffer CAD will not survive.
Tetiana Marynenko, Tetiana Halenova, Nataliia Raksha, Tetiana Vovk, Yuliya Tyravska, Olexii Savchuk, Liudmyla Ostapchenko   +6 more
doaj   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source